PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Latest Episodes:

Boris Sepesi, MD / Tina Cascone, MD, PhD - Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do Mar 16, 2022

Show notes

Go online to PeerView.com/FYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How have the best practices for multidisciplinary management of patients with stage I-III lung cancer changed now that adjuvant EGFR-targeted therapy has become the new standard of care in resected early-stage EGFR-mutated NSCLC, and what are the implications for thoracic surgeons and other key members of the lung cancer care team?, This PeerView Candid Conversations & Clinical Consults educational activity, based on a recent live broadcast, answers these and other burning questions. Experts in thoracic surgery and medical oncology come together to discuss recent advances and provide practical, case-based guidance on the importance of biomarker testing in early-stage settings. In addition, they provide direction on how to determine which patients are appropriate candidates for adjuvant EGFR-targeted therapy, if adjuvant chemotherapy is still needed, which considerations should be discussed with patients, and how thoracic surgeons, medical oncologists, pathologists, and other relevant specialists can effectively work together to determine the best multimodal treatment approach for each patient with stage I-III NSCLC. Upon completion of this CE activity, participants will be able to: Discuss the role of EGFR mutations in NSCLC, importance of identifying patients with EGFR mutations in earlier disease settings, and role of thoracic surgeons in biomarker testing and treatment selection in the era of precision oncology, Apply the latest evidence and recommendations to identify patients with early-stage NSCLC who would benefit from adjuvant EGFR-targeted therapy, Implement multidisciplinary strategies and shared decision-making to optimize biomarker testing and integration of adjuvant EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage NSCLC.

Sam Cheng, MD / Angela Pham, MD - Short Bowel Syndrome IMPACT Initiative: An Initiative to Individualize Treatment and Improve the Pediatric to Adult Healthcare Transition Mar 15, 2022

Show notes

Go online to PeerView.com/SWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses new and emerging therapies addressing unmet patient needs in the management of schizophrenia and bipolar disorder. Upon completion of this activity, participants should be better able to: Describe the barriers and challenges associated with the treatment of patients with schizophrenia and bipolar disorder, Assess the mechanisms of action, efficacy, safety, and tolerability profiles of available and emerging therapies for the management of schizophrenia and bipolar disorder, Incorporate shared decision-making between the interprofessional healthcare team and patients in the individualized management of schizophrenia and bipolar disorder to maximize treatment and mitigate adverse events and disease relapse.

Rohit Loomba, MD, MHSc - Test Your Knowledge of What’s Now and What’s Next: Modification of Metabolic Risk Factors to Improve Liver-Related and Cardiovascular‐Related Outcomes in NASH Mar 01, 2022

Show notes

Go online to PeerView.com/FCW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hepatology provides practical guidance across the spectrum of care from screening and diagnosis to management of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants should be better able to: Discuss the epidemiology and disease burden of NAFLD/NASH, Describe the relationship between NAFLD/NASH and cardiovascular disease, Assess current and emerging treatments for NASH in the context of mechanism of action (eg, ability to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression) and current clinical evidence (eg, impact on fibrosis and cardiovascular risk; safety)

Tammie L.S. Benzinger - The Expanding Role of Neuroimaging in Alzheimer’s Disease Diagnosis and Management: Is Radiology Prepared for New Challenges? Mar 01, 2022

Show notes

Go online to PeerView.com/KZA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A multidisciplinary panel of experts discuss the expanding role of neuroimaging in the diagnosis and management of Alzheimer’s disease. Upon completion of this CE activity, participants will be able to: Assess the relative utility of the structural, functional, and molecular neuroimaging techniques used in AD diagnosis and management, Implement an evidence-based, guideline-directed approach to using neuroimaging to assess amyloid burden when confirming a diagnosis of AD or determining patient eligibility for use of amyloid-lowering therapy, Apply validated neuroimaging techniques and biomarkers to monitor for treatment response, disease progression, and ARIA or other adverse events in patients being treated for AD, Employ a patient-centered, multidisciplinary approach to patient care in AD

Paneez Khoury - Easing the Burden of Hypereosinophilic Syndrome: An Animated Exploration of the Role of Targeted Therapy to Improve Patient Outcomes Feb 28, 2022

Show notes

Go online to PeerView.com/DMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hypereosinophilic syndrome discusses the burden, symptoms, and differential diagnosis of the disease, as well as the latest data on treatment. Upon completion of this CE activity, participants will be able to: Describe the burden of hypereosinophilic syndrome (HES) on patients, including the consequences of underdiagnosed and undertreated HES, Explain the role of eosinophils in the pathophysiology of HES, Identify features of HES that differentiate the diagnosis from other eosinophilic disorders, Develop treatment plans for patients with HES based on subtype and the latest clinical evidence.

William D. Tap, MD - Practice Points in TGCT: Updates on Safe Use of Novel Systemic Options Feb 23, 2022

Show notes

Go online to PeerView.com/UVR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Understanding practical considerations with systemic therapy in tenosynovial giant cell tumor (TGCT) can be critical for safe delivery of therapy. In this activity, an expert medical oncologist provides a practical update on targeted treatment options for TGCT management, with a focus on safe delivery of care—including appropriate dosing, food effects, and safety considerations—based on the current clinical experience with approved CSF1R inhibitors. Upon completion of this CE activity, participants will be able to: Manage safety and dosing considerations with targeted agents in the setting of TGCT.

Michael Heinrich, MD - Optimally Sequencing Modern TKIs in GIST: Expert Perspectives From an Interprofessional Sarcoma Team Feb 23, 2022

Show notes

Go online to PeerView.com/CPH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While TKIs have been a mainstay in the first three lines of treatment for patients with gastrointestinal stromal tumors (GISTs), new discoveries and emerging science have led to the development of newer agents that address treatment resistance. Known as modern TKIs, these agents have a confirmed role in the treatment of patients with specific mutations or in later-line settings and are now being tested in earlier-stage disease. While oncologists, oncology nurses, and other members of the interdisciplinary cancer care team have new opportunities for increasing survival and improving QOL in their patients with unresectable/metastatic GIST, they are also faced with more complex treatment paradigms that must account for mutation profiling, treatment selection/sequencing, symptom and AE management, psychological support, and nutritional considerations. Join our experts to hear how all members of the cancer care team can work together to effectively incorporate these modern TKIs into clinical practice. Upon completion of this CE activity, participants will be able to: Summarize current clinical evidence on established (ie, standard and newly available) and emerging TKI strategies (ie, modern TKIs in early-line settings) for unresectable/metastatic GIST, Sequence appropriate targeted therapy over multiple lines of treatment for patients with unresectable/metastatic GIST, Develop personalized treatment plans that address effective safety, dosing, and QOL strategies associated with the use of TKIs with an interprofessional team of clinicians who care for patients with unresectable/metastatic GIST.

Alan "Tony" Amberg - Addressing Unmet Needs in the Management of Schizophrenia and Bipolar Disorder: New and Emerging Therapeutic Options to Enhance Treatment and Maximize Patient Outcomes Feb 23, 2022

Show notes

Go online to PeerView.com/JUV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses new and emerging therapies addressing unmet patient needs in the management of schizophrenia and bipolar disorder. Upon completion of this activity, participants should be better able to: Describe the barriers and challenges associated with the treatment of patients with schizophrenia and bipolar disorder, Assess the mechanisms of action, efficacy, safety, and tolerability profiles of available and emerging therapies for the management of schizophrenia and bipolar disorder, Incorporate shared decision-making between the interprofessional healthcare team and patients in the individualized management of schizophrenia and bipolar disorder to maximize treatment and mitigate adverse events and disease relapse.

Christian B. Ramers, MD, MPH, AAHIVS - A Closer Look at Telehealth for HIV: Best Practices for Patient Management in a Unique Era of Care Feb 22, 2022

Show notes

Go online to PeerView.com/WXQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases discusses using telehealth to provide care to patients with HIV. Upon completion of this CE activity, participants should be better able to: Discuss how telehealth is transforming access to quality care and treatment for people with HIV during the coronavirus pandemic, Outline the telehealth technical resources available to manage patients living with HIV, Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth, services by the healthcare team to provide HIV care.

Professor Thomas Powles, MBBS, MRCP, MD - Carrying Through in Advanced/Metastatic Urothelial Carcinoma: Expert Perspectives on Recent Practice‐Changing Data and the Practicalities of Individualizing and Continuing Care With Novel Immunotherapy Maintenance Strategies Feb 22, 2022

Show notes

Go online to PeerView.com/RVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Improving outcomes for patients with advanced urothelial carcinoma (UC) has been challenging, with many patients experiencing only short periods of progression-free survival after treatment with first-line chemotherapy. A game changer in many cancers, immunotherapy has provided new avenues for the cancer care team to help their patients with advanced UC live longer. In particular, new data on the use of immunotherapy in the first-line maintenance setting has shown that using immunotherapy before patients’ progress to the second-line setting increases survival without a negative impact on quality of life. In this activity, a panel of experts discusses strategies for incorporating these important data into individualized patient care. Upon completion of this CE activity, participants will be able to: Cite the available clinical evidence on the use of immune checkpoint inhibitors as first-line (1L) maintenance vs. delayed (2L) therapy in patients with advanced UC after response to 1L platinum chemotherapy, Select patients with advanced UC who may be eligible for 1L maintenance therapy with an immune checkpoint inhibitor based on response to initial chemotherapy, PD-L1 status, and other patient- and disease-related factors, Incorporate new clinical evidence and updated guideline recommendations on 1L immunotherapy maintenance regimens into current treatment algorithms for patients with advanced UC.